Additionally, we aimed to evaluate the predictive efficacy of a de-escalated chemotherapy with trastuzumab and pertuzumab in selected HER2-positive breast cancer, and to determine whether the THP regimen can be used as an alternative to TCbHP or AC-THP in such cases. This evidence concerns the gene ERBB2 and breast cancer.